EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 96 filers reported holding EPIZYME INC in Q2 2022. The put-call ratio across all filers is 5.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $74,632 | -42.6% | 64,897 | +25.0% | 0.00% | – |
Q4 2021 | $130,000 | -50.2% | 51,916 | +2.0% | 0.00% | – |
Q3 2021 | $261,000 | -40.1% | 50,906 | -3.1% | 0.00% | – |
Q2 2021 | $436,000 | -5.2% | 52,521 | -0.6% | 0.00% | – |
Q1 2021 | $460,000 | -21.2% | 52,861 | -1.8% | 0.00% | -100.0% |
Q4 2020 | $584,000 | -6.4% | 53,808 | +2.9% | 0.00% | 0.0% |
Q3 2020 | $624,000 | -27.8% | 52,280 | -1.7% | 0.00% | 0.0% |
Q2 2020 | $864,000 | +12.4% | 53,183 | +7.3% | 0.00% | 0.0% |
Q1 2020 | $769,000 | -33.4% | 49,565 | +5.5% | 0.00% | 0.0% |
Q4 2019 | $1,155,000 | +132.4% | 46,970 | -3.8% | 0.00% | 0.0% |
Q3 2019 | $497,000 | -18.9% | 48,840 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $613,000 | +23.6% | 48,840 | +22.0% | 0.00% | 0.0% |
Q1 2019 | $496,000 | +112.0% | 40,022 | +5.7% | 0.00% | – |
Q4 2018 | $234,000 | -38.6% | 37,870 | +5.3% | 0.00% | – |
Q3 2018 | $381,000 | -30.2% | 35,955 | -10.7% | 0.00% | -100.0% |
Q2 2018 | $546,000 | -18.0% | 40,284 | +7.5% | 0.00% | 0.0% |
Q1 2018 | $666,000 | +38.2% | 37,484 | -2.5% | 0.00% | 0.0% |
Q4 2017 | $482,000 | -22.0% | 38,451 | +18.5% | 0.00% | 0.0% |
Q3 2017 | $618,000 | +23.4% | 32,446 | -2.1% | 0.00% | 0.0% |
Q2 2017 | $501,000 | -8.9% | 33,137 | +3.3% | 0.00% | 0.0% |
Q1 2017 | $550,000 | +60.3% | 32,069 | +12.9% | 0.00% | – |
Q4 2016 | $343,000 | +19.5% | 28,407 | -2.5% | 0.00% | – |
Q3 2016 | $287,000 | -2.0% | 29,148 | +1.8% | 0.00% | – |
Q2 2016 | $293,000 | +10.6% | 28,638 | +24.4% | 0.00% | – |
Q1 2016 | $265,000 | -16.7% | 23,020 | +16.2% | 0.00% | – |
Q4 2015 | $318,000 | +26.7% | 19,816 | +1.4% | 0.00% | – |
Q3 2015 | $251,000 | -45.3% | 19,542 | +2.2% | 0.00% | -100.0% |
Q2 2015 | $459,000 | +171.6% | 19,123 | +111.8% | 0.00% | – |
Q1 2015 | $169,000 | +3.7% | 9,028 | +4.8% | 0.00% | – |
Q4 2014 | $163,000 | -32.1% | 8,611 | -2.6% | 0.00% | – |
Q3 2014 | $240,000 | -12.1% | 8,842 | +0.5% | 0.00% | – |
Q2 2014 | $273,000 | +143.8% | 8,794 | +79.4% | 0.00% | – |
Q1 2014 | $112,000 | +6.7% | 4,903 | -3.2% | 0.00% | – |
Q4 2013 | $105,000 | -45.3% | 5,066 | +5.7% | 0.00% | – |
Q3 2013 | $192,000 | – | 4,792 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
BP PLC | 24,687 | $28,000 | 0.16% |
NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |